Skip to main content

Advertisement

SpringerLink
Log in

Osteochemonecrosis: An Overview

  • Update in Gnathic Pathology. Guest Editors: Angela Chi, DMD and John Wright, DDS
  • Published:
Head and Neck Pathology Aims and scope Submit manuscript

Abstract

Osteonecrosis of the jaw to a certain extent has been with us for many years. But recently the advent of various medications such as bisphosphonates, VEGF inhibitors, tyrosine kinase inhibitors and humanized antibodies to osteoclastic action have resulted in thousands of cases. While the bisphosphonates continue to be the most common medication associated with osteochemonecrosis antibodies such as denosumab which irreversibly act on osteoclastic action are also being reported. This narrative review will serve as an update with a focus on some of the histopathologic features discussed and reviewed. Perhaps even more uncommonly seen in past reports a discussion of features possibly observed while grossing specimens will be discussed. At the end of this report is hoped that the pathologist will have a better understanding of the historical features, clinical settings, gross examination features as well as histopathologic features associated with osteochemonecrosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Dorland’s Illustrated Medical Dictionary. 30th ed. Philadelphia: W.B. Saunders and Co.; 2000.

  2. Almazrooa SA, Woo SB. Bisphosphonate and nonbisphosphonate-associated osteonecrosis of the jaw: a review. J Am Dent Assoc. 2009;140(7):864–75.

    Article  CAS  PubMed  Google Scholar 

  3. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61(9):1115–7.

    Article  PubMed  Google Scholar 

  4. Handick K. The effect of etidronate on alveolar bone remodeling in dog mandible, University of Indiana; 1998.

  5. Gotcher JE, Jee WS. The progress of the periodontal syndrome in the rice rat. II. The effects of a diphosphonate on the periodontium. J Periodontal Res. 1981;16(4):441–55.

    Article  CAS  PubMed  Google Scholar 

  6. Gotcher JE, Jee WS. The progress of the periodontal syndrome in the rice rat. I. Morphometric and autoradiographic studies. J Periodontal Res. 1981;16(3):275–91.

    Article  CAS  PubMed  Google Scholar 

  7. Ruggiero SL, Mehrotra B, Rosenberg TJ, et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004;62(5):527–34.

    Article  PubMed  Google Scholar 

  8. Lugassy G, Shaham R, Nemets A, et al. Severe osteomyelitis of the jaw in long-term survivors of multiple myeloma: a new clinical entity. AmJMed. 2004;117(6):440–1.

    Google Scholar 

  9. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006;144(10):753–61.

    Article  CAS  PubMed  Google Scholar 

  10. Hellstein JW, Adler RA, Edwards B, et al. Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc. 2011;142(11):1243–51.

    Article  CAS  PubMed  Google Scholar 

  11. Ruggiero SL, Dodson TB, Fantasia J, et al. American association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw—2014 update. J Oral Maxillofac Surg. 2014;72(10):1938–56.

    Article  PubMed  Google Scholar 

  12. Migliorati CA. Bisphosphanates and oral cavity avascular bone necrosis. J Clin Oncol. 2003;21(22):4253–4.

    Article  PubMed  Google Scholar 

  13. Migliorati CA. Bisphosphonate-associated oral osteonecrosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005;99(2):135.

    Article  PubMed  Google Scholar 

  14. Migliorati CA, Casiglia J, Epstein J, et al. Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper. J Am Dent Assoc. 2005;136(12):1658–68.

    Article  CAS  PubMed  Google Scholar 

  15. Migliorati CA, Schubert MM, Peterson DE, et al. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer. 2005;104(1):83–93.

    Article  CAS  PubMed  Google Scholar 

  16. Russell RG, Rogers MJ, Frith JC, et al. The pharmacology of bisphosphonates and new insights into their mechanisms of action. J Bone Miner Res. 1999;14(Suppl 2):53–65.

    Article  CAS  PubMed  Google Scholar 

  17. Fleisch H. Introduction to bisphosphonates. History and functional mechanisms. Orthopade. 2007;36(2):103.

    CAS  Google Scholar 

  18. Wood J, Bonjean K, Ruetz S, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther. 2002;302(3):1055–61.

    Article  CAS  PubMed  Google Scholar 

  19. Santini D, Vespasiani GU, Vincenzi B, et al. The antineoplastic role of bisphosphonates: from basic research to clinical evidence. AnnOncol. 2003;14(10):1468–76.

    CAS  Google Scholar 

  20. Vitte C, Fleisch H, Guenther HL. Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption. Endocrinology. 1996;137(6):2324–33.

    CAS  PubMed  Google Scholar 

  21. Maines E, Monti E, Doro F, et al. Children and adolescents treated with neridronate for osteogenesis imperfecta show no evidence of any osteonecrosis of the jaw. J Bone Miner Metab. 2012;30(4):434–8.

    Article  CAS  PubMed  Google Scholar 

  22. Aghaloo TL, Felsenfeld AL, Tetradis S. Osteonecrosis of the jaw in a patient on Denosumab. J Oral Maxillofac Surg. 2010;68(5):959–63.

    Article  PubMed Central  PubMed  Google Scholar 

  23. Cummings SR, San MJ, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756–65.

    Article  CAS  PubMed  Google Scholar 

  24. Fusco V, Galassi C, Berruti A, et al. Osteonecrosis of the jaw after zoledronic acid and denosumab treatment. J Clin Oncol. 2011;29(17):e521–2 author reply e523-524.

    Article  PubMed  Google Scholar 

  25. Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011;29(9):1125–32.

    Article  CAS  PubMed  Google Scholar 

  26. Lipton A, Fizazi K, Stopeck AT, et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer. 2012;48(16):3082–92.

    Article  CAS  PubMed  Google Scholar 

  27. Miller PD, Bolognese MA, Lewiecki EM, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone. 2008;43(2):222–9.

    Article  CAS  PubMed  Google Scholar 

  28. Papapoulos S, Chapurlat R, Libanati C, et al. Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res. 2012;27(3):694–701.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  29. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28(35):5132–9.

    Article  CAS  PubMed  Google Scholar 

  30. Troeltzsch M, Woodlock T, Kriegelstein S, et al. Physiology and pharmacology of nonbisphosphonate drugs implicated in osteonecrosis of the jaw. J Can Dent Assoc. 2012;78:c85.

    PubMed  Google Scholar 

  31. Bozas G, Roy A, Ramasamy V, et al. Osteonecrosis of the jaw after a single bisphosphonate infusion in a patient with metastatic renal cancer treated with sunitinib. Onkologie. 2010;33(6):321–3.

    Article  PubMed  Google Scholar 

  32. Brunello A, Saia G, Bedogni A, et al. Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma. Bone. 2009;44(1):173–5.

    Article  CAS  PubMed  Google Scholar 

  33. Hoefert S, Eufinger H. Sunitinib may raise the risk of bisphosphonate-related osteonecrosis of the jaw: presentation of three cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;110(4):463–9.

    Article  PubMed  Google Scholar 

  34. Disel U, Besen AA, Ozyilkan O, et al. A case report of bevacizumab-related osteonecrosis of the jaw: old problem, new culprit. Oral Oncol. 2012;48(2):e2–3.

    Article  PubMed  Google Scholar 

  35. Estilo CL, Fornier M, Farooki A, et al. Osteonecrosis of the jaw related to bevacizumab. J Clin Oncol. 2008;26(24):4037–8.

    Article  PubMed  Google Scholar 

  36. Greuter S, Schmid F, Ruhstaller T, et al. Bevacizumab-associated osteonecrosis of the jaw. Ann Oncol. 2008;19(12):2091–2.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  37. Guarneri V, Miles D, Robert N, et al. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat. 2010;122(1):181–8.

    Article  CAS  PubMed  Google Scholar 

  38. Hopp RN, Pucci J, Santos-Silva AR, et al. Osteonecrosis after administration of intravitreous bevacizumab. J Oral Maxillofac Surg. 2012;70(3):632–5.

    Article  PubMed  Google Scholar 

  39. Koch FP, Walter C, Hansen T, et al. Osteonecrosis of the jaw related to sunitinib. Oral and maxillofacial surgery. 2011;15(1):63–6.

    Article  PubMed  Google Scholar 

  40. Smidt-Hansen T, Folkmar TB, Fode K, et al. Combination of zoledronic Acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma. J Oral Maxillofac Surg. 2013;71(9):1532–40.

    Article  PubMed  Google Scholar 

  41. Nakamura T, Shiraki M, Fukunaga M, et al. Effect of the cathepsin K inhibitor odanacatib administered once weekly on bone mineral density in Japanese patients with osteoporosis–a double-blind, randomized, dose-finding study. Osteoporos Int. 2014;25(1):367–76.

    Article  CAS  PubMed  Google Scholar 

  42. Zhuo Y, Gauthier JY, Black WC, et al. Inhibition of bone resorption by the cathepsin K inhibitor odanacatib is fully reversible. Bone. 2014;67:269–80.

    Article  CAS  PubMed  Google Scholar 

  43. Lee JJ, Cheng SJ, Jeng JH, et al. Successful treatment of advanced bisphosphonate-related osteonecrosis of the mandible with adjunctive teriparatide therapy. Head Neck. 2011;33(9):1366–71.

    Article  PubMed  Google Scholar 

  44. Subramanian G, Cohen HV, Quek SY. A model for the pathogenesis of bisphosphonate-associated osteonecrosis of the jaw and teriparatide’s potential role in its resolution. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011;112(6):744–53.

    Article  PubMed  Google Scholar 

  45. Subramanian G, Quek SY. Teriparatide’s role in the management of bisphosphonate-associated osteonecrosis of the jaw. Osteoporos Int. 2012;23(11):2727–8 author reply 2729-2730.

    Article  CAS  PubMed  Google Scholar 

  46. McClung MR, Grauer A, Boonen S, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014;370(5):412–20.

    Article  CAS  PubMed  Google Scholar 

  47. Castillo H, Samson-Fang L, Academy American, for Cerebral P, et al. Effects of bisphosphonates in children with osteogenesis imperfecta: an AACPDM systematic review. Dev Med Child Neurol. 2009;51(1):17–29.

    Article  PubMed  Google Scholar 

  48. Hennedige AA, Jayasinghe J, Khajeh J, et al. Systematic review on the incidence of bisphosphonate related osteonecrosis of the jaw in children diagnosed with osteogenesis imperfecta. J Oral Maxillofac Res. 2013;4(4):e1.

    PubMed Central  PubMed  Google Scholar 

  49. Malmgren B, Astrom E, Soderhall S. No osteonecrosis in jaws of young patients with osteogenesis imperfecta treated with bisphosphonates. J Oral Pathol Med. 2008;37(4):196–200.

    Article  CAS  PubMed  Google Scholar 

  50. Bagan JV, Hens-Aumente E, Leopoldo-Rodado M, et al. Bisphosphonate-related osteonecrosis of the jaws: study of the staging system in a series of clinical cases. Oral Oncol. 2012;48(8):753–7.

    Article  CAS  PubMed  Google Scholar 

  51. Carlson ER, Basile JD. The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2009;67(5 Suppl):85–95.

    Article  PubMed  Google Scholar 

  52. Ruggiero SL, Carlson ER, Assael LA. Comprehensive review of bisphosphonate therapy: implications for the oral and maxillofacial surgery patient. J Oral Maxillofac Surg. 2009;67(5 Suppl):1.

    Article  PubMed  Google Scholar 

  53. Carlson ER. Management of antiresorptive osteonecrosis of the jaws with primary surgical resection. J Oral Maxillofac Surg. 2014;72(4):655–7.

    Article  PubMed  Google Scholar 

  54. Carlson ER, Fleisher KE, Ruggiero SL. Metastatic cancer identified in osteonecrosis specimens of the jaws in patients receiving intravenous bisphosphonate medications. J Oral Maxillofac Surg. 2013;71(12):2077–86.

    Article  PubMed  Google Scholar 

  55. Fleisher KE, Welch G, Kottal S, et al. Predicting risk for bisphosphonate-related osteonecrosis of the jaws: CTX versus radiographic markers. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;110(4):509–16.

  56. Hansen T, Kunkel M, Kirkpatrick CJ, et al. Actinomyces in infected osteoradionecrosis–underestimated? Hum Pathol. 2006;37(1):61–7.

    Article  PubMed  Google Scholar 

  57. Hall V. Actinomyces–gathering evidence of human colonization and infection. Anaerobe. 2008;14(1):1–7.

    Article  CAS  PubMed  Google Scholar 

  58. Hansen T, Kunkel M, Springer E, et al. Actinomycosis of the jaws–histopathological study of 45 patients shows significant involvement in bisphosphonate-associated osteonecrosis and infected osteoradionecrosis. Virchows Archiv. 2007;451(6):1009–17.

    Article  PubMed  Google Scholar 

  59. Naik NH, Russo TA. Bisphosphonate-related osteonecrosis of the jaw: the role of actinomyces. Clin Infect Dis. 2009;49(11):1729–32.

    Article  PubMed  Google Scholar 

  60. De Ceulaer J, Tacconelli E, Vandecasteele SJ. Actinomyces osteomyelitis in bisphosphonate-related osteonecrosis of the jaw (BRONJ): the missing link? Eur J Clin Microbiol Infect Dis. 2014;33(11):1873–80.

  61. Favia G, Pilolli GP, Maiorano E. Histologic and histomorphometric features of bisphosphonate-related osteonecrosis of the jaws: an analysis of 31 cases with confocal laser scanning microscopy. Bone. 2009;45(3):406–13.

    Article  CAS  PubMed  Google Scholar 

  62. Favia G, Piattelli A, Sportelli P, et al. Osteonecrosis of the posterior mandible after implant insertion: a clinical and histological case report. Clin Implant Dent Relat Res. 2011;13(1):58–63.

    Article  PubMed  Google Scholar 

  63. Marx RE, Tursun R. Response to—a commentary on “Suppurative osteomyelitis, bisphosphonate induced 1 osteonecrosis, osteoradionecrosis: a blinded histopathologic comparison and its 2 implications for the mechanism of each disease” by R.E. Marx and R. Tursun [Int. J. Oral. Maxillofac. Surg. 41 (3) (2012) 283–289]. Int J Oral Maxillofac Surg. 2013;42(1):148–9.

    Article  CAS  PubMed  Google Scholar 

  64. Marx RE, Tursun R. Suppurative osteomyelitis, bisphosphonate induced osteonecrosis, osteoradionecrosis: a blinded histopathologic comparison and its implications for the mechanism of each disease. Int J Oral Maxillofac Surg. 2012;41(3):283–9.

    Article  CAS  PubMed  Google Scholar 

  65. Kalmar JR. A commentary on “Suppurative osteomyelitis, bisphosphonate induced osteonecrosis, osteoradionecrosis: a blinded histopathologic comparison and its implications for the mechanism of each disease” by R.E. Marx and R. Tursun [Int. J. Oral Maxillofac. Surg. 41 (2012) 283–289]. Int J Oral Maxillofac Surg. 2013;42(1):147–8.

    Article  PubMed  Google Scholar 

  66. Weinstein RS, Roberson PK, Manolagas SC. Giant osteoclast formation and long-term oral bisphosphonate therapy. N Engl J Med. 2009;360(1):53–62.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  67. Jain N, Weinstein RS. Giant osteoclasts after long-term bisphosphonate therapy: diagnostic challenges. Nat Rev Rheumatol. 2009;5(6):341–6.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  68. Sedghizadeh PP, Kumar SK, Gorur A, et al. Identification of microbial biofilms in osteonecrosis of the jaws secondary to bisphosphonate therapy. J Oral Maxillofac Surg. 2008;66(4):767–75.

    Article  PubMed  Google Scholar 

  69. Sedghizadeh PP, Kumar SK, Gorur A, et al. Microbial biofilms in osteomyelitis of the jaw and osteonecrosis of the jaw secondary to bisphosphonate therapy. J Am Dent Assoc. 2009;140(10):1259–65.

    Article  PubMed  Google Scholar 

  70. Mauri D, Valachis A, Polyzos IP, et al. Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: a meta-analysis. Breast Cancer Res Treat. 2009;116(3):433–9.

    Article  CAS  PubMed  Google Scholar 

  71. Van PC. The phenomenon of osteonecrosis of the jaw in patients with metastatic breast cancer. Cancer Invest. 2006;24(1):110–2.

    Article  Google Scholar 

  72. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22(10):1479–91.

    Article  PubMed  Google Scholar 

  73. Estilo CL, Van Poznak CH, Wiliams T, et al. Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy. Oncologist. 2008;13(8):911–20.

    Article  PubMed  Google Scholar 

  74. Van Poznak C. Making a case for defining osteonecrosis of the jaw. J Dent Res. 2011;90(4):399–401.

    Article  PubMed Central  PubMed  Google Scholar 

  75. Van Poznak CH, Temin S, Yee GC, et al. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol. 2011;29(9):1221–7.

    Article  PubMed  Google Scholar 

  76. Saad F, Brown JE, Van Poznak C, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol. 2012;23(5):1341–7.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Iowa, Iowa City, IA, USA

    John Hellstein

Authors
  1. John Hellstein
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John Hellstein.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hellstein, J. Osteochemonecrosis: An Overview. Head and Neck Pathol 8, 482–490 (2014). https://doi.org/10.1007/s12105-014-0583-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12105-014-0583-z

Keywords

Search

Navigation